NTHI NeOnc Technologies Holdings, Inc.
Price Chart
Executive Summary
NeOnc reported Q1 2026 EPS of -$0.38, a 245.5% miss vs consensus of -$0.11, with zero revenue. The net loss improved YoY to $8.8M from $32.3M due to lower non-cash stock-based compensation, but cash burn remains high at ~$6.1M/quarter. The company highlighted a $10M PIPE from Cinctive Capital and an undrawn $10M line of credit, funding operations into September 2026, while advancing NEO212 and NEO100 clinical programs with an interim readout expected in August 2026.
Actionable Insight
The severe EPS miss and minimal cash runway (into Sep 2026) despite a $10M PIPE signal high dilution risk and potential need for additional capital. Traders should watch for the NEO100 interim data readout (~Aug 2026) as a binary catalyst, but the near-term financial fragility and lack of revenue make this a high-risk speculative name. The CEO's insider purchase provides some confidence but does not offset the fundamental cash burn.
Key Facts
- Q1 2026 EPS of -$0.38 missed consensus of -$0.11 by 245.5%
- Zero revenue reported; clinical-stage biopharma with no approved products
- Net loss improved to $8.8M from $32.3M YoY, driven by lower non-cash stock-based compensation
- Cash and cash equivalents of $138,601 as of March 31, 2026; plus $10M PIPE and $10M undrawn line of credit expected to fund operations into September 2026
- Normalized cash operating expenses of ~$6.1M/quarter (~$24.4M annualized)
- NEO212 Phase 1 complete; RP2D set at 610 mg; planning Type B End-of-Phase 1 FDA meeting
- NEO100 Phase 2a fully enrolled; interim data readout expected ~August 2026
- CEO purchased >$500K of shares in open market
- Appointed David Choi as Chief Accounting Officer
Financial Impact
EPS miss of -$0.27 vs consensus; net loss of $8.8M; cash runway only into September 2026 despite PIPE
Risk Factors
- Cash runway only into September 2026; likely need for additional dilutive financing
- No revenue; clinical-stage with no approved products
- NEO212 and NEO100 clinical data may fail to meet endpoints
- High cash burn rate of ~$24.4M annualized relative to current cash position
- Stock-based compensation remains significant at $2.7M/quarter
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3296670 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
1d ago
|
8-K
| $4.55 awaiting T+5 | awaiting T+5 | — | $4.75 (−4.40%) |
|
May 18, 2026
25d ago
|
8-K
| $5.48 $4.84 | ▼ −11.77% | ▼ −14.07% | $4.75 (−13.32%) |
|
May 18, 2026
25d ago
|
Press Release
| $5.34 $5.14 | ▲ +3.75% | ▲ +5.36% | $4.75 (+11.05%) |
|
May 5, 2026
5w ago
|
10-K/A
| $4.99 $5.51 | ▲ +10.42% | ▲ +8.44% | $4.75 (−4.81%) |
|
Apr 24, 2026
7w ago
|
8-K
| $4.61 $4.14 | ▲ +10.20% | ▲ +10.60% | $4.75 (−3.04%) |
|
Apr 23, 2026
7w ago
|
Insider Cluster
| $4.30 $5.31 | ▲ +23.49% | ▲ +20.38% | $4.75 (+10.47%) |
|
Apr 23, 2026
7w ago
|
Insider Cluster
| $4.79 $4.30 | ▼ −10.23% | ▼ −11.71% | $4.75 (−0.84%) |
|
Apr 17, 2026
8w ago
|
EFFECT
| $5.34 $4.78 | ▼ −10.49% | ▼ −11.04% | $4.75 (−11.05%) |
|
Apr 16, 2026
8w ago
|
8-K
| $5.34 $4.78 | ▼ −10.49% | ▼ −11.04% | $4.75 (−11.05%) |
|
Apr 16, 2026
8w ago
|
424B5
| $5.34 $4.78 | ▲ +10.49% | ▲ +11.04% | $4.75 (+11.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access